Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells
Authors
Keywords
-
Journal
BLOOD
Volume 137, Issue 12, Pages 1694-1697
Publisher
American Society of Hematology
Online
2020-11-11
DOI
10.1182/blood.2020007150
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
- (2020) G. J. Ossenkoppele et al. LEUKEMIA
- Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
- (2020) Harinder Gill et al. Cancer Medicine
- A real-world study on Clofarabine and Cytarabine combination in patients with relapsed/refractory acute myeloid leukemia
- (2019) Claudio Fozza Mediterranean Journal of Hematology and Infectious Diseases
- GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
- (2019) Adriano Venditti et al. BLOOD
- Clofarabine and cytarabine for acute myeloid leukaemia
- (2019) Robert Stirrups LANCET ONCOLOGY
- Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia
- (2019) Yoshimitsu Shimomura et al. LEUKEMIA & LYMPHOMA
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
- (2018) Wendelien Zeijlemaker et al. LEUKEMIA
- Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization
- (2018) Gerrit J Schuurhuis et al. Expert Review of Hematology
- Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission
- (2017) Xavier Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework
- (2016) Oriana Ciani et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
- (2015) D. Grimwade et al. BLOOD
- An update of current treatments for adult acute myeloid leukemia
- (2015) H. Dombret et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started